Minerva

The progression of rheumatoid arthritis and other stories . . .

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4678 (Published 22 July 2014) Cite this as: BMJ 2014;349:g4678

Single biomarkers are of limited use in predicting whether newly diagnosed rheumatoid arthritis will progress quickly or slowly, but a combination of 12 different biomarkers can identify a group at very low risk of radiographic progression in the first year. This is what the SWEFOT triallists found when they looked back at the 235 patients with newly diagnosed rheumatoid arthritis they enrolled for a randomised trial (Annals of the Rheumatic Diseases 2014, doi:10.1136/annrheumdis-2013-204986). It remains to be seen whether their multi-biomarker disease activity (MBDA) score will prove useful in clinical practice.

As John Yudkin and Victor Montori recently pointed out in The BMJ, the term “prediabetes” has more to do with disease mongering than with medicine. But the Diabetes Prevention Program Outcomes Study shows that people who leave the prediabetic category by normalising their glucose metabolism reap the reward in lower indices of cardiovascular risk (Diabetes Care 2014, doi:10.2337/dc14-0656). During the course of this study, all …

View Full Text

Sign in

Log in through your institution

Subscribe